Фармакологический тромболизис: что нового?

УДК 616-005.6:615.036.8

Аннотация

Фармакологический тромболизис широко применяется для ликвидации жизнеугрожающих тромбозов. Эта медицинская технология постоянно усовершенствуется. Разрабатываются гибридные фармако-хирургические технологии. Наиболее широко применяется системный тромболизис на основе активаторов плазминогена. Также внедряются новые технологии системного тромболизиса на основе новых препаратов — не активаторов плазминогена. Разработана концепция неплазминового фибринолиза. На её основе предложен метод фармакологического тромболизиса на основе ферментов субтилизинов.

ЛИТЕРАТУРА

1. Dexter L., Folch-Pi W. Venous thrombosis. An account of the first documented case. JAMA. 1974;228(2):195–6. DOI: 10.1001/ jama.228.2.195.

2. Virchow R.L.K. Gesammelte Abhandlungen zur wissenschaftlichen Medicin. Frankfurt am Main: Von Meidinger & Sohn, 1856.

3. Лобастов К.В., Дементьева Г.И., Лаберко Л.А. Современные

   представления об этиологии и патогенезе венозного тромбоза: переосмысление триады Вирхова. Флебология. 2019;13(3):227– 35. DOI: 10.17116/flebo201913031227.

4. BrownD.D.Caseofthrombosisoftheheartandoftherightfemoral vein; with fatty disease of the kidneys. Br Med J. 1868;19;2(416):632. DOI: 10.1136/bmj.2.416.632.

5. TilletW.S.,GarnerR.L.Thefibrinolyticactivityofhemolyticstreptococci. J Exp Med. 1933;58(4):485–502. DOI: 10.1084/jem.58.4.485.

6. FletcherA.P., Alkjaersig N., SmyrniotisF.E., Sherry S.The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians. 1958;71:287–96.

7. Чазов Е.И., Матвеева Л.С., Мазаев А.В. Внутрикоронарное назначение фибринолизина при остром инфаркте миокарда. Терапевтический архив. 1976;48(4):8–19.

8. Ibanez B., James S., Agewall S. et al; ESC Scientific Document

   Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119– 77. DOI: 10.1093/eurheartj/ehx393.

9. Mosimah C.I., Murray P.J., Simpkins J.W. Not all clots are created equal: a review of deficient thrombolysis with tissue plasminogen activator (tPA) in patients with metabolic syndrome. Int J Neurosci. 2019;129(6):612–618. DOI: 10.1080/00207454.2018.1550400.

10. RaoS.S.,AgasthiP.Thrombolysisinmyocardialinfarction(TIMI) risk score. StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing, 2020.

11. Tian J.W., Zhu M., Wang F.Q. et al. Intracoronary arterial retrograde thrombolysis with percutaneous coronary intervention: a novel use of thrombolytic to treat acute ST-segment elevation myocardial infarction. J Geriatr Cardiol. 2019;16(6):458–67. DOI: 10.11909/j.issn.1671–5411.2019.06.004.

12. FuY., GuX.S., HaoG.Z. et al. Comparison of myocardial microcirculatory perfusion after catheter-administered intracoronary thrombolysis with anisodamine versus standard thrombus aspiration in patients with ST-elevation myocardial infarction. Catheter Cardiovasc Interv. 2019;93(S1):839–45. DOI: 10.1002/ccd.28112.

13. Домашенко М.А., Максимова М.Ю., Танашян М.М. Системный тромболизис при ишемическом инсульте: клинические факторы персонифицированной эффективности и безопасности. Анналы клинической и экспериментальной неврологии. 2019;13(1):5–14. DOI: 10.25692/ACEN.2019.1.1.

14. Zitek T., Ataya R., Brea I. Using tenecteplase for acute ischemic stroke: what is the hold up? West J Emerg Med. 2020;21(2):199– 202. DOI: 10.5811/westjem.2020.1.45279.

15. ThomallaG.,SimonsenC.Z.,BoutitieF.etal.MRI-guidedthrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379:611–22. DOI: 10.1056/NEJMoa1804355.

16. Barow E., Boutitie F., Cheng B. et al.; WAKE-UP Investigators. Functional outcome of intravenous thrombolysis in patients with lacunar infarcts in the WAKE-UP Trial. JAMA Neurol. 2019;76(6):641– 9. DOI: 10.1001/jamaneurol.2019.0351.

17. Galinovic I., Boutitie F., Fiebach J.B. et al. Post-hoc analysis of outcome of intravenous thrombolysis in infarcts of infratentorial localization in the WAKE-UP Trial. Front Neurol. 2019;10:983. DOI: 10.3389/fneur.2019.00983.
18. Campbell B.C., Mitchell P.J., Churilov L. et al. Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study. Int J Stroke. 2019 Sep 30:1747493019879652. DOI: 10.1177/1747493019879652. [Epub ahead of print].
19. Kadir R.R.A., Bayraktutan U. Urokinase plasminogen activator: A potential thrombolytic agent for ischaemic stroke. Cell Mol Neurobiol. 2020;40(3):347–55. DOI: 10.1007/s10571-019-00737-w.
20. Haeberlin M.I., Held U., Baumgartner R.W. et al. Impact of intravenous thrombolysis on functional outcome in patients with mild ischemic stroke without large vessel occlusion or rapidly improving symptoms. Int J Stroke. 2019 Sep 12:1747493019874719. DOI: 10.1177/1747493019874719. [Epub ahead of print].
21. Majidi S., Luby M., Lynch J.K. et al. MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS. Neurology. 2019;93(16):e1507-e1513. DOI: 10.1212/ WNL.0000000000008312.
22. Menichelli A., Furlanis G., Sartori A. et al. Thrombolysis’ benefits on early post-stroke language recovery in aphasia patients. J Clin Neurosci. 2019;70:92–5. DOI: 10.1016/j.jocn.2019.08.064.
23. Lin J., Liang Y., Lin J. Endovascular therapy versus intravenous thrombolysis in cervical artery dissection-related ischemic stroke: a meta-analysis. J Neurol. 2019 Jul 18. DOI: 10.1007/s00415-01909474-y. [Epub ahead of print].
24. Campbell B.C.V., Ma H., Ringleb P.A. et al.; EXTEND, ECASS-4, and EPITHET Investigators. Extending thrombolysis to 4,5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet. 2019;394(10193):139–47. DOI: 10.1016/S0140–6736(19)31053–0.
25. Fraticelli L., Freyssenge J., Claustre C. et al.; on behalf of the RESUVal Group. Sex-related differences in management and outcome of acute ischemic stroke in eligible patients to thrombolysis. Cerebrovasc Dis. 2019;47(3–4):196–204. DOI: 10.1159/000500901.
26. Feda S., Nikoubashman O., Schürmann K. et al. Endovascular stroke treatment does not preclude high thrombolysis rates. Eur J Neurol. 2019;26(3):428-e33. DOI: 10.1111/ene.13831.
27. Li Y., Wang H., Zhao L. et al. A case report of thrombolysis resistance: thrombus ultrastructure in an ischemic stroke patient. BMC Neurol. 2020;20(1):135. DOI: 10.1186/s12883-020-01706-3.
28. Holliday E., Lillicrap T., Kleinig T. et al. Developing a multivariable prediction model for functional outcome after reperfusion therapy for acute ischaemic stroke: study protocol for the Targeting Optimal Thrombolysis Outcomes (TOTO) multicentre cohort study. BMJ Open. 2020;10(4):e038180. DOI: 10.1136/bmjopen-2020–038180.
29. Izcovich A., Criniti J.M., Popoff F. et al. Thrombolytics for venous thromboembolic events: a systematic review with metaanalysis. Blood Adv. 2020;4(7):1539–53. DOI: 10.1182/bloodadvances.2020001513.
30. Tsai C.J., Lee C.Y. Comparative outcomes of catheter-directed thrombolysis plus rivaroxaban vs rivaroxaban alone in patients with acute iliofemoral deep vein thrombosis. J Chin Med Assoc. 2019;82(12):902–8. DOI: 10.1097/JCMA.0000000000000206.

31. Weinberg I., Vedantham S., Salter A. et al.; ATTRACT Trial Investigators. Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial. Vasc Med. 2019;24(5):442–51. DOI: 10.1177/1358863X19862043.

32. Alhazmi L., Moustafa A., Mangi M.A. et al. Efficacy and safety of catheter-directed thrombolysis in preventing post-thrombotic syndrome: A meta-analysis. Cureus. 2019;11(2):e4152. DOI: 10.7759/cureus.4152.

33. Gao G., Zhu S., Xie Z. et al. Efficacy of catheter-directed thrombolysis on post-burn deep venous thrombosis of lower extremity. J Coll Physicians Surg Pak. 2019;29(5):448–52. DOI: 10.29271/ jcpsp.2019.05.448.

34. Ascher E., Chait J., Pavalonis A. et al. Fast-track thrombolysis protocol: A single-session approach for acute iliofemoral deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2019;7(6):773–80. DOI: 10.1016/j.jvsv.2019.06.018.

35. Rabuffi P., Vagnarelli S., Bruni A. et al. Pharmacomechanical catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis: our case series. Eur Rev Med Pharmacol Sci. 2019;23(5):2244– 52. DOI: 10.26355/eurrev_201903_17272.

36. ХоревН.Г.,БеллерА.В.,БоровиковЭ.В.идр.Сравнительнаяэффективность различных тромболитических средств при лечении тромбоэмболии легочной артерии. Ангиология и сосудистая хирургия. 2019;25(3):23–8. DOI: 10.33529/ANGI02019316.

37. Gauchel N., Bode C., Duerschmied D. New aspects of thrombolysis and thrombectomy in pulmonary embolism. Herz. 2019;44(4):324– 29. DOI: 10.1007/s00059-019-4801-z.

38. Zuin M., Rigatelli G., Carraro M. et al. Systemic thrombolysis in haemodynamically unstable pulmonary embolism: The earlier the better? Thromb Res. 2019;173:117–23. DOI: 10.1016/j. thromres.2018.11.029.

39. Das Gupta J., Marek J., Rana M.A., Guliani S. Same-day ICU discharge in selected patients with severe submassive pulmonary embolism treated with catheter-directed thrombolysis. Vasc Endovascular Surg. 2020;54(1):58–64. DOI: 10.1177/1538574419872047.

40. D’Auria S., Sezer A., Thoma F. et al. Outcomes of catheter-directed thrombolysis vs. standard medical therapy in patients with acute submassive pulmonary embolism. Pulm Circ. 2020;10(1):2045894019898368. DOI: 10.1177/2045894019898368.

41. Rao G., Xu H., Wang J.J. et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute pulmonary embolism: A multicenter comparison of patient-centered outcomes. Vasc Med. 2019;24(3):241–7. DOI: 10.1177/1358863X19838334.

42. deWinterM.A.,HartE.A.,vandenHeuvelD.A.F.etal.Localultrasound-facilitated thrombolysis in high-risk pulmonary embolism: first Dutch experience. Cardiovasc Intervent Radiol. 2019;42(7):962– 9. DOI: 10.1007/s00270-019-02200-1.

43. Knox M.F., Langholz D.E., Berjaoui W.K., Eberhart L. Preservation of cardiopulmonary function in patients treated with ultrasound-accelerated thrombolysis in the setting of submassive pulmonary embolism. J Vasc Interv Radiol. 2019;30(5):734–41. DOI: 10.1016/j.jvir.2018.08.027.

44. Chen H.A., Ma Y.H., Hsu T.Y., Chen J.P. Preparation of peptide and recombinant tissue plasminogen activator conjugated poly(LacticCo-Glycolic Acid) (PLGA) magnetic nanoparticles for dual targeted thrombolytic therapy. Int J Mol Sci. 2020;21(8). pii: E2690. DOI: 10.3390/ijms21082690.

45. Li C., Zhang L., Wang C. et al. N-acetyl-seryl-aspartyl-lysyl-proline augments thrombolysis of tPA (tissue-type plasminogen activator) in aged rats after stroke. Stroke. 2019;50(9):2547–54. DOI: 10.1161/strokeaha.119.026212.

46. Engelberger R.P., Schroeder V., Nagler M. et al. Enhanced thrombolysis by ultrasound-assisted catheter-directed thrombolysis and microbubbles in an in vitro model of iliofemoral deep vein thrombosis. Thromb Haemost. 2019;119(7):1094–101. DOI: 10.1055/ s-0039–1688973.

47. Zhu Q., Dong G., Wang Z. et al. Intra-clot microbubble-enhanced ultrasound accelerates catheter-directed thrombolysis for deep vein thrombosis: A clinical study. Ultrasound Med Biol. 2019;45(9):2427–33. DOI: 10.1016/j.ultrasmedbio.2019.04.022.
48. Liao J., Ren X., Yang B. et al. Targeted thrombolysis by using cRGD-modified N, N, N-Trimethyl Chitosan nanoparticles loaded with lumbrokinase. Drug Dev Ind Pharm. 2019;45(1):88–95. DOI: 10.1080/03639045.2018.1522324.
49. Мадонов П.Г., Момот А.П., Мамаев А.Н. и др. Неплазминовый фибринолиз субтилизинами. Тромбоз, гемостаз и реология. 2019;(3):24–32. DOI: 10.25555/THR.2019.3.0886.
50. Мишенина С.В., Мадонов П.Г., Байкалов Г.И. и др. Пероральный тромболизис при венозных тромбозах (клиническое исследование). Тромбоз, гемостаз и реология. 2019;(4):54–67. DOI: 10.25555/THR.2019.4.0900